APA (7th ed.) Citation

Noringriis, I. M., Donia, M., Madsen, K., Schmidt, H., Haslund, C. A., Bastholt, L., . . . Ellebaek, E. (2025). Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab. British Journal of Cancer, 133(3), 337. https://doi.org/10.1038/s41416-025-03048-8

Chicago Style (17th ed.) Citation

Noringriis, Inge Mansfield, Marco Donia, Kasper Madsen, Henrik Schmidt, Charlotte Aaquist Haslund, Lars Bastholt, Inge Marie Svane, and Eva Ellebaek. "Long-term Clinical Outcome of Patients with Metastatic Melanoma and Initial Stable Disease During Anti-PD-1 Checkpoint Inhibitor Immunotherapy with Pembrolizumab." British Journal of Cancer 133, no. 3 (2025): 337. https://doi.org/10.1038/s41416-025-03048-8.

MLA (9th ed.) Citation

Noringriis, Inge Mansfield, et al. "Long-term Clinical Outcome of Patients with Metastatic Melanoma and Initial Stable Disease During Anti-PD-1 Checkpoint Inhibitor Immunotherapy with Pembrolizumab." British Journal of Cancer, vol. 133, no. 3, 2025, p. 337, https://doi.org/10.1038/s41416-025-03048-8.